Events2Join

FDA Approves Eli Lilly Weight Drug


FDA Approves New Medication for Chronic Weight Management

The FDA approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity or overweight with at least one ...

FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight ...

FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight ...

FDA Approves Diabetes Drug Tirzepatide for Chronic Weight ...

Eli Lilly will market tirzepatide as a weight loss drug under the name Zepbound. Tirzepatide is already approved to treat adults with type 2 ...

New GLP-1 weight loss drug Zepbound approved by FDA

The FDA recently approved a new Eli Lilly drug, Zepbound (tirzepatide), for chronic weight management in adults with at least one ...

Weight loss drug Zepbound is now available, Eli Lilly says - CNN

The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company's (NYSE. The FDA approved Zepbound last month for chronic weight ...

What to know about Zepbound, Eli Lilly's new weight loss drug

Zepbound belongs to a new class of medications, alongside Ozempic and Wegovy, that have skyrocketed in popularity in the U.S.. FDA approves ...

FDA approves new version of diabetes drug Mounjaro to be sold for ...

The US Food and Drug Administration approved Eli Lilly's Zepbound, or tirzepatide. The drug helped dieters lose about a quarter of their body weight, or 60 ...

Tirzepatide earns FDA approval for obesity treatment - Healio

... weight management among adults with obesity, according to a press release. Tirzepatide (Zepbound, Eli Lilly) has been approved for use by ...

FDA approves potent Eli Lilly obesity drug, Zepbound - STAT News

Eli Lilly's blockbuster drug tirzepatide, sold as Mounjaro for type 2 diabetes, has been cleared to treat obesity, making it the second in a ...

FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and ...

U.S. Food and Drug Administration (FDA) approved Mounjaro™ (tirzepatide) injection, Eli Lilly and Company's (NYSE: LLY) new once-weekly GIP ...

FDA approves weight loss drug from Eli Lilly that helped people lose ...

The FDA has approved Zepbound, an injectable weight loss drug from Eli Lilly that helped people lose up to 52 lbs in 16 months during ...

Eli Lilly Wins FDA Nod for Obesity Drug That Rivals Wegovy, Ozempic

Mounjaro was approved last year as a treatment for adults with type 2 diabetes. The dramatic weight-loss effects seen in studies have driven off ...

Zepbound: FDA approves Eli Lilly's diabetes drug Mounjaro for ...

Made by Eli Lilly, it's part of a new class of drugs that includes semaglutide, known as Ozempic for diabetes and Wegovy for weight loss, which ...

FDA Approves Tirzepatide for Treating Obesity - Medscape

The US Food and Drug Administration (FDA) has approved tirzepatide for chronic weight management in adults with obesity or overweight. Eli Lilly ...

FDA approves Eli Lilly drug tirzepatide for weight loss - CNBC

The Food and Drug Administration on Wednesday approved Eli Lilly 's blockbuster drug tirzepatide for weight loss, paving the way for even wider ...

FDA approves a new weight loss drug, Zepbound from Eli Lilly

The medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.

FDA approves new version of Eli Lilly's diabetes drug for weight loss

FDA approves new version of Eli Lilly's diabetes drug for weight loss.

Lilly weight-loss drug gets US, UK approval to rival Wegovy - Reuters

After Wednesday's FDA approval, Lilly can now promote the drug for weight loss. The approval was based partly on data from a late-stage trial of ...

FDA Approves Eli Lilly's Zepbound for Chronic Weight Management

Lilly's Zepbound (tirzepatide) injection is the first and only approved treatment that activates two incretin hormone receptors, ...

FDA approves new obesity drug from Eli Lilly named Zepbound

The Food and Drug Administration on Wednesday approved Eli Lilly's diabetes drug for treating obesity, opening the door for widespread insurance coverage.